The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data.
Andreia BorgesFilipa PereiraPatrícia RedondoLuís AntunesCláudia VieiraPedro AntunesMaria José BentoSusana SousaJosé Machado LopesFrancisco Rocha-GonçalvesJoaquim Abreu de SousaDeolinda Sousa PereiraMarina BorgesPublished in: Health economics review (2021)
ICER was more favourable in stage III HR negative BC patients compared to other patient profiles. Innovative treatments access is critical to deliver high-quality healthcare, but sustainability must be considered. These results suggest the importance of establishing a cost-effectiveness profile of Pertuzumab in NeoT for HER2-positive BC.
Keyphrases
- healthcare
- end stage renal disease
- ejection fraction
- chronic kidney disease
- epidermal growth factor receptor
- newly diagnosed
- lymph node
- squamous cell carcinoma
- metastatic breast cancer
- big data
- machine learning
- patient reported outcomes
- deep learning
- combination therapy
- artificial intelligence
- tyrosine kinase
- replacement therapy
- life cycle
- smoking cessation